Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-11-08

FDA Approved: QUVIVIQ — Supplemental Application (Idorsia Pharmaceuticals Ltd)

View source ↗

Summary

FDA approved a supplemental application for QUVIVIQ (daridorexant) from Idorsia Pharmaceuticals Ltd, updating the product labeling for the treatment of insomnia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • QUVIVIQ (daridorexant)

Snippet

SUPPL AP for QUVIVIQ (DARIDOREXANT)